This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cigna's (CI) New Pathwell Suite to Boost Efficiency, Lower Cost
by Zacks Equity Research
Cigna (CI) expects to bump up its Pathwell suite's availability throughout the next year.
Are Investors Undervaluing Centene (CNC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Humana (HUM) have performed compared to their sector so far this year.
Zacks Industry Outlook Highlights UnitedHealth Group, Humana, Centene and Molina Healthcare
by Zacks Equity Research
UnitedHealth Group, Humana, Centene and Molina Healthcare are part of Zacks Industry Outlook article.
4 HMO Stocks to Watch Despite Escalating Technology Expenses
by Debasmita Chatterjee
A growing customer base and numerous contract wins might drive the Medical-HMO industry. However, high expenses related to technology advancements and a shortage of nurses will dampen margins. Stocks like UNH, HUM, CNC and MOH will likely ride out the industry storms.
Humana (HUM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $493.91, marking a +0.67% move from the previous day.
Company News for Sep 21, 2022
by Zacks Equity Research
Companies in The News Are: F,HUM,CHNG,UNH,CGNX
Humana (HUM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Humana (HUM) closed at $499.79 in the latest trading session, marking a +0.51% move from the prior day.
Cigna's (CI) Arm Adds Five Digital Health Apps to Its Platform
by Zacks Equity Research
Cigna's (CI) unit bolsters its clinical platform Digital Health Formulary by including five on-line solutions, aiming to relieve people from chronic medical conditions.
Humana (HUM) Surges 8.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Humana (HUM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is Humana (HUM) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Company News for Sep 16, 2022
by Zacks Equity Research
Companies in The News Are: MSFT, HUM, CTRA, ADBE
Humana (HUM) Hikes Guidance: Here's Why It's a Good Sign
by Zacks Equity Research
Humana (HUM) shaking off the discrete COVID-19 headwind from its guidance is an important milestone for the Medical - HMOs space.
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed at $486.36 in the latest trading session, marking a +0.97% move from the prior day.
UnitedHealth Group (UNH) Ties Up to Aid Medicare Members
by Zacks Equity Research
UnitedHealth Group (UNH) teams up with Walmart to follow a collaborative approach in extending advanced healthcare services to Medicare members at specific Walmart Health locations.
Humana vs. UnitedHealth: What's the Better Buy?
by Derek Lewis
It's not easy to choose between these two healthcare heavyweights. Still, one must come out on top.
Factors that Make Humana (HUM) an Attractive Bet Now
by Zacks Equity Research
Humana (HUM) continues to gain on continued top-line growth resulting from its solid Medicaid and Medicare businesses. A strong cash position enables HUM to undertake growth-related investments.
Humana (HUM) Brings Home Health Unit of KAH Under CenterWell
by Zacks Equity Research
Humana (HUM) wraps up rebranding KAH's home health operations to the CenterWell brand. This leads to the clubbing of HUM's three payer-agnostic care services into a common suite.
Is Humana (HUM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Humana (HUM) and Alimera Sciences (ALIM) have performed compared to their sector so far this year.
Is Humana (HUM) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights Tesla, Exxon Mobil, Marriott International, Humana and Visa
by Zacks Equity Research
Tesla, Exxon Mobil, Marriott International, Humana and Visa are part of The Zacks top Analyst Blog.
Encompass Health's (EHC) Future Hospital to Serve Pennsylvania
by Zacks Equity Research
Encompass Health (EHC) decides to develop a 50-bed inpatient rehabilitation hospital in Pennsylvania to better serve the rehabilitative needs of the local communities.
Forget Meltdown, Each Dip Offers a Solid Entry Point: 5 Picks
by Nalak Das
we have narrowed our search to five U.S. corporate giants to buy-on-the-dip to generate handsome profits in the mid-to-long-term. These are: TSLA, XOM, V, HUM and MAR.
Humana (HUM) Brand to Open Senior-Centric Centers in Arizona
by Zacks Equity Research
Humana's (HUM) CenterWell brand announces plans to open nine centers by early 2023 to serve the aging population of the Phoenix region.
Humana (HUM) to Acquire Inclusa to Aid Medicaid Customer Base
by Zacks Equity Research
Humana (HUM) inks a deal to purchase Wisconsin-based Inclusa to grow its Medicaid membership and fortify its footprint in the state.